$0.23
-0.04 (-13.46%)
Open$0.25
Previous Close$0.26
Day High$0.26
Day Low$0.21
52W High$0.91
52W Low$0.08
Volume—
Avg Volume171.8K
Market Cap9.13M
P/E Ratio—
EPS$-0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,571.1% upside
Current
$0.23
$0.23
Target
$3.76
$3.76
$2.62
$3.76 avg
$5.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.55M | 7.84M | 7.68M |
| Net Income | -34,409,431 | -2,005,672 | -1,738,578 |
| Profit Margin | -619.8% | -25.6% | -22.6% |
| EBITDA | -35,017,161 | -2,263,216 | -2,551,790 |
| Free Cash Flow | — | -1,406,564 | -1,071,377 |
| Rev Growth | — | +12.8% | +0.1% |
| Debt/Equity | 0.06 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |